ANXA2
ATC code L01
Abemaciclib
Acalabrutinib
Adagrasib
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Antigen
Antineoplastic
Asciminib
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
B-cell maturation antigen
BRAF (gene)
Baricitinib
Bcr-abl fusion protein
Belantamab mafodotin
Bermekimab
Bevacizumab
Bi-specific T-cell engager
Binimetinib
Blinatumomab
Bosutinib
Boxed warning
Breakthrough therapy
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD38-IN-78c
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Cancer immunotherapy
Capmatinib
Catumaxomab
Cediranib
Cemiplimab
Ceritinib
Cetuximab
Chemical formula
ClinicalTrials.gov
Cobimetinib
Committee for Medicinal Products for Human Use
Copanlisib
Copyright status of works by the federal government of the United States
Cosibelimab
Cough
Crizotinib
Cytokine release syndrome
Dabrafenib
Dacomitinib
DailyMed
Dalpiciclib
Daratumumab
Dasatinib
Decreased appetite
Denileukin diftitox
Diarrhea
Dinutuximab beta
Doi (identifier)
Dostarlimab
DrugBank
Drug nomenclature
Drugs.com
Durvalumab
Duvelisib
EML4
Edrecolomab
Elotuzumab
Elranatamab (data page)
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
European Medicines Agency
Everolimus
Exotoxin
Fatigue
Fedratinib
Fibroblast growth factor receptor
Filgotinib
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
HER2/neu
Hdl (identifier)
Health Canada
Hedgehog signaling pathway
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Immunotherapy
Inavolisib
Indicated
Infigratinib
Injection site reaction
Inotuzumab ozogamicin
Interleukin 2
International nonproprietary name
Ipilimumab
Isatuximab
Janus kinase
KEGG
KRAS
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Loncastuximab tesirine
Lorlatinib
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Masitinib
Medication
MedlinePlus
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Mosunetuzumab
Moxetumomab pasudotox
Multiple myeloma
Musculoskeletal pain
Myeloid
Nausea
Naxitamab
Necitumumab
Neratinib
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Oportuzumab monatox
Orelabrutinib
Orphan drug
Osimertinib
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pazopanib
Pembrolizumab
Pemigatinib
Pertuzumab
Pexidartinib
Pfizer
Pi3K inhibitor
Pirtobrutinib
Platelet-derived growth factor receptor
Pneumonia
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Priority review
Proapoptotic
Prohibitin
Prolgolimab
Proteasome inhibitor
Public domain
Pyrexia
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Rash
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Ripretinib
Rituximab
Rociletinib
Route of administration
Ruxolitinib
Sabatolimab
Sacituzumab govitecan
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Sirolimus
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Subcutaneous administration
Subcutaneous injection
Sugemalimab
Sunitinib
T cell
Tafasitamab
Talquetamab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Teclistamab
Temsirolimus
Tepotinib
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Toripalimab
Tositumomab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tyrosine kinase inhibitor
Unique Ingredient Identifier
Upper respiratory tract infection
VEGF receptors
Vandetanib
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vemurafenib
Venetoclax
Vismodegib
World Health Organization
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab